Genprex (GNPX) said Tuesday that its lead drug candidate Reqorsa demonstrated positive results in a preclinical study in mice.

In one mice group that was supplemented with the Reqorsa gene therapy, Genprex said tumor growth was diminished and there was a "significant reduction in T reg" as well as a "significant increase in Cytotoxic T cells." Compared to the control group, the mice supplemented with Reqorsa also demonstrated a "significant increase in Granzyme B expression within Cytotoxic T cells and NK cells."

Separately, the company said it received a letter from Nasdaq's Listing Qualifications Department on Monday stating it regained compliance with the minimum bid price requirement.

Shares were down almost 11% in recent trading.

Price: 1.80, Change: -0.22, Percent Change: -10.89